Plain-English translation of NCT04698564 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new type of MRI scan called metabolic magnetic resonance imaging to see if it can help doctors diagnose prostate cancer and understand how serious it is. The scan works differently from standard MRI by showing how cancer cells use energy in a unique way. Researchers want to make sure this new imaging method is safe and works well in men with prostate cancer.
Current ways to diagnose and evaluate prostate cancer have limitations. This new type of MRI scan may provide better information about which cancers are aggressive and need treatment, helping doctors make better decisions about care and potentially sparing some men from unnecessary procedures.
If you qualify, you will receive the new metabolic MRI scan as part of your regular prostate cancer evaluation or treatment planning. The scan is performed in the same way as a standard MRI but uses a special type of contrast agent to show how cancer cells function. Your participation is part of this two-stage pilot study with about 20 participants to make sure the scan is safe and useful for men with prostate cancer.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
University of Maryland, Baltimore
Enrollment target
~4 participants
Started
December 2020
Primary completion
December 2025
Age range
40 Years – 80 Years
Sex
Male only
Last updated on clinicaltrials.gov in July 2026.